


Form PTO-1449		Docket Number (Optional) TUU-P02-006		Application Number 09/601,432		
<b>INFORMATION DISCLOSURE CITATION</b> <b>IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>		Applicant Bacovchin et al.				
		Filing Date January 5, 2001 <del>2001</del> 2001		Group Art Unit 16574		
<div style="text-align: center;"> <b>U.S. PATENT DOCUMENTS</b> </div>						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JR	AA	5,834,428	Drucker	514	12	<div style="text-align: center;"> <b>RECEIVED</b>  JUN 04 2002  TECH CENTER 1600/2900 </div>
JR	AB	5,061,811	Pinori et al.	549	274	
JR	AC	4,522,752	Sisto et al.	530	314	
<b>FOREIGN PATENT DOCUMENTS</b>						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO
<b>OTHER DOCUMENTS</b>						
<i>(Including Author, Title, Date, Pertinent Pages Etc.)</i>						
JR	AD	Bell et al., 1983, "Exon duplication and divergence in the human preproglucagon gene", Nature 304(5924):368-71				
JR	AE	Bell et al., 1983, "Hamster preproglucagon contains the sequence of glucagon and two related peptides", Nature 302(5910):716-8				
JR	AF	Conlon, 1988, "Proglucagon-derived peptides: nomenclature, biosynthetic relationships and physiological roles", Diabetologia 31(8):563-6				
JR	AG	Coruzzi et al., 1989, "Gastric antisecretory activity of telenzepine, a new M1-selective muscarinic antagonist: comparison with pirenzepine", Arch Int Pharmacodyn Ther 302:232-41				
JR	AH	Deacon et al., 1995, "Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects", Diabetes 44(9):1126-31				
JR	AI	Dupre, 1991, "Influences of the gut on the endocrine pancreas" <u>The Endocrine Pancreas</u> (Raven Press, New York) pp.253-281				
JR	AJ	Ebert et al., 1987, "Gastrointestinal peptides and insulin secretion", Diabetes Met. Rev. 3:1-26				
JR	AK	Gutniak et al., 1992, "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus", N Engl J Med 326(20):1316-22				
JR	AL	Habener et al., 1991, "Biosynthesis of glucagon" <u>The Endocrine Pancreas</u> (Raven Press, New York) pp. 53-71 <i>Biosynthesis</i>				
JR	AM	Holst et al., 1987, "Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut", FEBS Lett. 211(2):169-74				
JR	AN	Kawashima et al., 1990, "Pharmacological differentiation of presynaptic M1 muscarinic receptors modulating acetylcholine release from postsynaptic muscarinic receptors in guinea-pig ileum", Gen Pharmacol 21(1):17-21				

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)		Docket Number (Optional) TUU-P02-006	Application Number 09/601,432
		Applicant Bacovchin et al.	
		Filing Date January 5, 2001	Group Art Unit 1653 1657
CIP E JC MAY 28 2002 PATENT & TRADEMARK OFFICE	AO	Kinder et al., 1985, "Acylamino boronic acids and difluoroborane analogues of amino acids: potent inhibitors of chymotrypsin and elastase", J Med Chem 28(12):1917-25	
	AP	Kreymann et al., 1987, "Glucagon-like peptide-1 7-36: a physiological incretin in man", Lancet 2(8571):1300-4	
JR	AQ	Kubiak et al., 1994, "Metabolism of mouse growth hormone-releasing factor, mGRF(1-42)OH, and selected analogs from the bovine GRF series in mouse and bovine plasma in vitro", Pept Res 7(3):153-61	
JR	AR	Lambrecht et al., 1989, "Pharmacology of hexahydro-difenidol, hexahydro-sila-difenidol and related selective muscarinic antagonists", Trends Pharmacol Sci 10(Suppl):60	
JR	AS	Lund et al., 1982, "Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem", Proc Natl Acad Sci U S A 79(2):345-9	
JR	AT	Matteson et al., 1984, "Synthesis and properties of pinanediol $\alpha$ -amino boronic acids", Organometallics 3:1284	
JR	AU	Mojsov et al., 1986, "Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing", J Biol Chem 261(25):11880-9	
JR	AV	Mojsov et al., 1987, "Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas", J Clin Invest 79(2):616-9	
JR	AW	Mojsov, 1992, "Structural requirements for biological activity of glucagon-like peptide-I", Int J Pept Protein Res 40(3-4):333-43	
JR	AX	Orskov et al., 1987, "Pancreatic and intestinal processing of proglucagon in man", Diabetologia 30(11):874-81	
JR	AY	Patzelt et al., 1979, "Identification and processing of proglucagon in pancreatic islets", Nature 282(5736):260-6	
JR	AZ	Pospisilik, John A. et al. Metabolism of Glucagon by Dipeptidyl Peptidase IV (CD26). <i>Regulatory Peptides</i> 96, 133-141 (2001).	
JR	BA	Radhakrishna et al., 1979, "New method for direct conversion of amides to amines", J Org Chem 44:1746	
JR	BB	Schmidt et al., 1985, "Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets", Diabetologia 28(9):704-7	
JR	BC	Shue et al., 1987, "Amide bond surrogates: a general synthetic route to trans carbon-carbon double bond isosteres", Tetrahedron Letters 28:3225	
JR	BD	Stanley et al., 1989, "Repeated hypothalamic stimulation with neuropeptide Y increases daily carbohydrate and fat intake and body weight gain in female rats", Physiol Behav 46(2):173-7	
JR	BE	Weir et al., 1989, "Glucagonlike peptide I (7-37) actions on endocrine pancreas", Diabetes 38(3):338-42	

RECEIVED  
 JUN 04 2002  
 TECH CENTER 1600/2900

PTO-1449 Form 1 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)		Docket Number (Optional) TUU-P02-006	Application Number 09/601,432
		Applicant Bacovchin et al.	
		Filing Date January 5, 2001	Group Art Unit 1653 1654
		Wilding et al., 1992, "Increased neuropeptide Y content in individual hypothalamic nuclei, but not neuropeptide Y mRNA, in diet-induced obesity in rats", J Endocrinol 132(2):299-304	
EXAMINER: PATENT & TRADEMARK OFFICE		DATE CONSIDERED November 7, 2002	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**RECEIVED**  
JUN 04 2002  
TECH CENTER 1600/2900